Journal article icon

Journal article

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.

Abstract:

This 6-month, open, non-controlled, multicenter, dose-titration study evaluated the efficacy and safety of 28-day prolonged-release (PR) lanreotide in the treatment of carcinoid syndrome. Eligible patients had a carcinoid tumor with > or =3 stools/day and/or > or =1 moderate/severe flushing episodes/day. Six treatments of 28-day PR lanreotide were administered by deep subcutaneous injection. The dose for the first two injections was 90 mg. Subsequent doses could be titrated (60, 90, 120...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1159/000082875

Authors


Ruszniewski, P More by this author
Ish-Shalom, S More by this author
Wymenga, M More by this author
O'Toole, D More by this author
Expand authors...
Journal:
Neuroendocrinology
Volume:
80
Issue:
4
Pages:
244-251
Publication date:
2004
DOI:
EISSN:
1423-0194
ISSN:
0028-3835
URN:
uuid:01df0f54-fdb6-4845-81eb-b8aa5dc41bc8
Source identifiers:
138682
Local pid:
pubs:138682

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP